|
Multiple Sclerosis
Treatments used to change the course of the disease
Updated in November 2007
(Press the F5 key in order to see the lastest
changes)
Approved
1.
Avonex (interferon beta 1a)
2.
Betaferon/Betaseron (interferon beta 1b)
3.
Betaferon (dosis 250 mcg). BENEFIT. BEtaferon® in Newly Emerging
Multiple Sclerosis For Initial Treatment (Schering)
4.
Copaxone (acetato de glatiramer)
5.
Novantrone (mitoxantrona)
6.
Rebif (nueva formulación libre de albúmina como
estabilizante) (interferon beta 1a)
7.
Tysabri (natalizumab)
Treatments not approved officially but frequently
used
1.
Antibiotics:
Doxiciclina, Amoxicilina, Rifampin, Metronidazola o Doxiciclina,
Roxitromicina, metronidazola
2.
Azatioprina (Imurel)
3.
Ciclofosfamida (Cytoxan)
4.
Inmunoglobulinas Intravenosas (IVIg)
5.
Intercambio plasmático (plasmaféresis)
6.
Low-Dose Naltrexone (LDN ó Naltrexona a Dosis Bajas)
7.
Metotrexato
8.
Micofenolato Mofetil (Cellcept)
Studies on Phase III
1.
BG-12 (Biogen)
2.
Campath-1H (Alemtuzumab) (Genzyme)
3.
Células Madre - Trasplante autólogo hematopoyético de
progenitores (HSCT)
Ensayo ASTIMS (Autologous Stem Cell Transplantation
International Multiple Sclerosis)
4.
Copaxone (dosis de 40 mg.) (Teva)
5.
FTY720 (fingolimod) (Novartis)
6.
Laquinimod (ABR-215062) (Teva)
7.
MBP8298 (BioMS) (ensayo para EM SP)
8.
Micofenolato Mofetil (Cellcept) (con Avonex)
9. Minociclina (MS Society de Canada, MS Scientific Research Foundation)
10.
Mylinax (cladribina oral) (Serono)
11. Progestina y Estradiol (Hospices Civils de Lyon)
12.
Revimmune (Ciclofosfamida a alta dosis o Cytoxan)
(Accentia
Biopharmaceuticals)
(EM severa)
13.
Rituximab (Rituxan) (Biogen / Genentech) (ensayo para
EM PP)
14.
Teriflunomida (HMR 1726) (Sanofi-Aventis)
15.
Trimesta (oral) (estriol) (con copaxone) (Pipex
Pharmaceuticals)
16.
Vacuna con células T (TCV-01-002) (Sheba Medical
Center)
(Doc.1
-
Doc.2)
Studies on Phase II
1.
A4I (RO0506997) (Hoffmann-La
Roche)
2.
Ácido alfa lipoico (con interferon beta) (EMSP)
(OHSU) Oregon Health & Science University
3.
Ácidos grasos Omega-3
4. Albuterol (Proventil) (con Copaxone)
5. Alferon (interferon alfa inyectado) (Hemispherx
Biopharma)
6. Anti-CD154 (conocido también como IDEC-131 o E6040) (Dartmouth
Medical School)
7. ATL-1102 (Antisense Therapeutics)
8. BCG (Bacille Calmette-Guérin) Vacuna
9.
BHT-3009-01 (Bayhill
Therapeutics) (con
Lipitor)
10.
Cannabinoides orales (EMPP) (Clinical
Neurology Research Group - Plymouth)
11. Células Madre (European
Charcot Foundation)
12. Células Madre Mesenquimales (Universidad
de Cambridge)
13.
CDP323 (UCB / Biogen)
14. Chaperonin 10 (XToll y Cpn10) (C-Bio)
15.
Cladribina oral y Rebif - Onward (Merck
Serono)
16.
Daclizumab (Zenapax) (Protein Design Labs, Biogen-Idec)
17. Doxiciclina (con Avonex)
18.
Enkorten (FAR404) (Farmacija)
19. Eritropoyetina (EPO) (Stem
Cell Therapeutics)
20. Estroprogestina (con IFN beta 1a) (Hospital
S. Andrea)
21. Fluoxetina (Prozac) (SP/PP MS) (University
Medical Center Groningen - Holanda)
22. GEM-SP (EM SP) (Gemacbio)
23. HP184 (ahora llamado nerispirdine) (Sanofi-Aventis)
23. IL-12/23 anticuerpo monoclonal (Dartmouth-Hitchcock
Medical Center)
24. Inosina (Thomas
Jefferson University)
25. Interferon alfa (Trat. oral) (Universidad de Texas-Houston)
26. Interferon-tau (tauferon) (Pepgen)
27. Kinurenina (Tranilast, Rizoben, 3,4-DAA) (Nuon
Therapeutics)
28. Lamotrigina (Lamictal) (EMSP) (GlaxoSmithkline)
30.
Low dose naltrexone (LDN, Naltrexona a dosis bajas) (UCSF)
31. Linfocitaféresis, Azatioprina y prednisona (EMSP) (Universidad
de Chicago)
32.
Lipitor (atorvastatina) (Pfizer) (con copaxone)
33. MBP8298 (BioMS) (ensayo para EM RR)
34. Metotrexato Intratecal (ITMTX)
35. Minociclina (Dos ensayos, uno con copaxone y otro con rebif)
36. MLN1202 (Millenium)
37. MN-166 (ibudilast y Ketas) (Medicinova)
38. N-Acetil-L-Cisteína (con copaxone)
39.
Neurovax (Orchestra
Therapeutics - Formerly Immune Response Corp)
40.
Ofatumumab (HuMax-CD20) (Genmab)
41. Pioglitazona (Actos)
42. Pirfenidona (Deskar) (Intermune) (ensayo para EM SP terminado)
43. Pixantrona (BBR 2778) (Cell Therapeutics)
44. Pravastatina (Hospital de la Universidad de Nantes - Francia)
45. RG2077 (CTLA4-IgG4m) (Immune Tolerance Network y Repligen)
46. Riluzole (Ritulex ®) (MultiCell
Technologies)
47. Rituximab (Rituxan) (Biogen / Genentech) (ensayo para EM RR)
48. RPI-78M (Nutra Pharma / ReceptoPharm)
49.
SB-683699 (T-0047 y Firategrast) (Trat. oral para EM RR) ((Glaxosmithkline
/
Tanabe)
50. Sunphenon EGCg (Galato de Epigalocatequina) (Charite
University, Berlin)
51. Testosterona (UCLA)
52. Topiramate (Topamax) (con Avonex)
53.
Tovaxin (Opexa)
54. Treosulfan (ensayo para EM SP) (
Universidad de Wuerzburg, Alemania)
55.
Vacunación con células T (Universidad
Transnacional de Limburg, Bélgica/Holanda)
56. Vitamina D3 (con calcio)
(Hospital St. Michael - Toronto)
57. Zocor (simvastatina) (Merck)
Studies on Phase I
1.
ATX-MS1467 (Apitope Technology)
2. AVE9897 (Sanofi-Aventis)
3. AZD 5904 (Astrazeneca)
4.
BCX-4208 (DADMe-Immunicillin-H ó R3421) (BioCryst
y
Roche)
5. Cannabinor (Pharmos)
6. CCX915 (CCR2 antagonist) (ChemoCentryx)
7. Citrato de Sildenafilo (Viagra)
8. DW908e (Trat. oral) (Daiichi)
9. Fotoféresis extracorpórea (FEC) (Universidad
de Milano Bicocca)
10. INCB8696 (Incyte)
11. JNK Inhibidor (Serono)
12. MDX1100 (Medarex)
13. MLN0415 (Millenium / Sanofi-Aventis)
14. MM-093 (FetoProteina alfa Recombinante Humana) (Merrimack)
15. MMP-12 Inhibidor (Serono)
16. NI-0401 (NovImmune)
17. NNZ-2566 (Neuren)
18. PI-2301 (Peptimmune)
19. R1295 (Roche)
20. RTL1000 (Artielle
ImmunoTherapeutics)
21. SC12267 (4SC AG)
22. SGN-30 (anticuerpo monoclonal Anti-CD30) (Seattle genetics)
23.
TK54 (LTKfarma)
Preclinical Studies
1.
AEG35156 (antagonista XIAP) (Aegera)
2.
2Aequorin (Quincy
Bioscience)
3. Arvanil (capsaicin sintético-anandamida híbrida)
4. AT-008 (Androclus)
5. AZD 8797 (Astrazeneca)
6.
Bloqueadores del canal de potasio Kv1.3
(Bionomics)
7.
Bowmann-Birk Inhibitor Concentrate (BBIC) (Jefferson
Medical College)
8. Calpeptin (inhibidor específico de Calpain) (Medical Univ. de
Carolina del Sur)
9. Cathepsin S (Medivir)
10. CD3 anticuerpo monoclonal Anti-CD3 (Harvard Medical School)
11. CD83 (Argos Therapeutics)
12. CEP-701 (Johns Hopkins)
13. CF101 (Can-Fite
BioPharma)
14. CF402 (Can-Fite
BioPharma)
15. CGEN-54 (Compugen)
16. CHR-1103 (Chromos)
17. Ciliary neurotrophic factor (CNTF)
18. Copaxone Oral (Teva)
19. CRA-028129 (inhibidor de la catepsina S ) (Schering)
20. CT301 (Universidad
de Western Ontario)
21. CYLA (inhibidor específico de Calpain) (SUNY
Downstate Medical Center)
22. DZ2002 (Shanghai
Institute of Materia Medica. SIMM)
23. Epratuzumab (IMMU-103/LymphoCide) (Immunomedics)
24.
Estrógeno receptor alfa (ERalpha).
Universidad de California (UCLA)
25. Fasudil (Kyushu
University)
26.
ESPRIT (Exon Skipping Pre-RNA Interference) (AVI
BioPharma)
27. Fenitoína (Dilantin) (Universidad
de Yale)
28. Gemfibrozil (Lopid)
29. GEMS-001 (Gemacbio)
30. Glial Growth Factor 2 (aka GGF2) (Acorda)
31. Glucosamina (Thomas Jefferson University)
32. hBCMA-Fc (La
Trobe University - Australia)
33. HE3204 (Hollis-Eden)
34. IL-1ra Terapia génica (Instituto
Científico Universitario San Raffaele, Milan)
35.
Inhibidores DP IV y APN (Universidad
Otto-von-Guericke, Alemania)
36. Interferon-beta - Electroporación (EP) mediante transferencia
genética de Interferón beta intramuscular) (Clínica
de Cleveland)
37. ISOTRETINOINA (Ácido 13-cis-retinoico) (KineMed, Inc.)
38. LF 15-0195 (Universidad Paul Sabatier, Francia)
39. LJP 1207 (La Jolla Pharmaceuticals)
40. LLDT-8 (Chinese
Academy of Sciences)
41. LX2931 (Lexicon Genetics)
42. MCT-175 (MultiCell)
43. Mikbeta1 (National Institutes of Health)
44.
MTA (metiltioadenosina) (Universidad de Navarra)
45.
MT203 (human anti-GM-CSF IgG1 antibody)
(Micromet AG)
46. NAPVSIPQ (NAP) (Allon)
47. Neurodur (Ceptor)
48. Neutrazumab (C5a Receptor antagonista) (G2 Therapies)
49.
Nicotinamida (una forma de vitamina B3) (Children's
Hospital - Boston)
50. ONO-2506 (ácido arúndico) (Ono
Pharmaceutical Company)
51. OPN-101 (Opsona)
52. Osteopontin (Serono)
53.
Peptidomiméticos de la apolipoproteina E (ApoE), COG133. (
Universidad de Duke )
54.
PLP-BPI (Universidad
de Kansas)
55. PXS2076 (Pharmaxis)
56. PXS25 / PXS64 (Pharmaxis)
57.
Q-Cells (Q
Therapeutics)
58. QR-442 (Quigley)
59. R348 (Rigel)
60. RheoSwitch Therapeutic System + TriGrid Delivery System (RheoGene,
Ichor Medical Systems)
61. ROB 895 (Oxypharma)
62. ShK(L5) (UC Irvine)
63. STA-5326 (Synta Pharmaceuticals)
64. sTNFR:Fc/p80 (Medical University of Lodz, Polonia)
65. Symadex (imidazoacridinona) (Xanthus)
66. Syntonix Transceptor/SynFusion (inhaled interferon-beta:Fc)
(Syntonix/Serono)
67.
Terapia inmunomoduladora Helmíntico-inducida (HINT) en EM RR.
(Universidad
de Wisconsin)
68. Tetracilina (no-antibacterial) (Paratek)
69. Timcodar (Recovexx)
70. Vasoactive Intestinal Peptide (aka VIP)
71. Vitamina B12 (Hospital for Sick Children - Toronto)
72.
VX15 (Vaccinex
y
Teva)
73. 15d-PGJ2 (Universidad de Arkansas)
74.
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR)
(Universidad
Médica de Carolina del Sur)
| UPDATED
SUMMARY |
| 7 |
Approved Treatments |
| 8 |
Treatments not officially approved (but used frequently)
|
| 16 |
Studies on
Phase III
|
| 57 |
Studies on Phase II
|
| 23 |
Studies on
Phase I |
| 74 |
Preclinical Studies |
|
185 Total Treatments |
A study
has found evidence of the virus Epstein-Barr (EBV) in the nerve tissues
of patients with MS: This evidence reveals a relationship between the
EBV and MS, but this doesn't prove to be the cause for it.
November 5th, 2007
National MS Society |
 |